Fosun Pharma Registers Comirnaty Vaccines in Hong Kong
Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced that Comirnaty (BNT162b2) and Comirnaty bivalent...
Fosun Pharmaceutical
Fosun Pharma Weighs Sale of India’s Gland Pharma Amid Market Interest
Shanghai Fosun Pharmaceutical Group Co. (HKG: 2196, SHA: 600196) is reportedly considering the sale of...
Fosun Pharma’s Gland Pharma to Acquire French CDMO Cenexi for EUR 120 Million
Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) announced that its India-based subsidiary, Gland Pharma Ltd...
Fosun Pharma’s Henlius Completes Clinical Trial Filing for HLX301 in Australia
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary,...
Shanghai Henlius Biotech to Provide R&D Services for COVID-19 Therapy Azvudine
China-based Shanghai Henlius Biotech (HKG: 2696) has entered into an agreement to provide clinical study...
PrimeLink Bio Raises Funds for ADC Development and R&D Expansion
Shenzhen-based drug developer PrimeLink Bio has reportedly raised “hundreds of millions” of renminbi in a...
Fosun Pharma’s Human Interferon Gamma Approved for New Indication by NMPA
Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced receiving another indication approval from the...
Fosun Pharma’s Bivalent COVID-19 Vaccine Comirnaty Authorized in Hong Kong
Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced obtaining emergency use authorization (EUA) in...
BioNTech’s Comirnaty Gets Limited Authorization in China Amid Scholz Visit
Germany-based mRNA specialist BioNTech (NASDAQ: BNTX) reportedly benefited from German Chancellor Olaf Scholz’s visit to...
Fosun Pharma Partners with Soong Ching Ling Foundation for Women and Children’s Health
The 5th China International Import Expo (CIIE) saw Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:...
Fosun Pharma Terminates Equity Transfer Deal with OncoCare Medical
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the termination of...
Eli Lilly Cancels Licensing Deal for Fosun Pharma’s FCN-338
Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its US partner...
Fosun Kite’s Yescarta Gains Priority Review Status for r/r LBCL
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture (JV) between Shanghai Fosun Pharmaceutical (Group)...
China Resources Partners with Fosun Pharma to Expand Global Healthcare Footprint
China Resources (Holdings) Co. Ltd (HKG: 3320) has entered into a strategic partnership with compatriot...
Fosun Pharma Launches 20ml SPSB Liquid Product in US Market
Shanghai Fosun Pharma (Group) Co., Ltd (SHA: 600196, HKG: 2196) has reported the market launch...
Fosun Pharma Signs Exclusive Licensing Deal for H008 with Carephar
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has signed an exclusive...
Celregen Licenses Regenerative Therapy CLS001 from Japan’s Cellusion
Hangzhou Celregen Therapeutics Ltd, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196),...
Fosun Pharma Inks Licensing Deal with Neovii for GvHD Therapy Grafalon
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) signed an exclusive licensing...
Fosun Pharma’s Controlling Shareholder to Sell 3% Stake for USD 461 Million
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its controlling shareholder, Shanghai Fosun...
Fosun Pharma’s H1 2022 Revenue Rises 25.9% on New Drug Launches, Global Expansion
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) reported RMB 21.34 billion (USD 3 billion)...